3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow XC221: new trials by email Literature Review of XC221 trials Research Report on XC221
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections XC221 100 mg, XC221 200 mg, Placebo - Influenza, Viral Respiratory Infection | Phase 2 | Completed | Valenta Pharm JSC | 255 | 2021-10-01 | 2023-07-27 |
| Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI XC221, Placebo - Influenza, Acute Respiratory Viral Infections | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2019-01-31 | 2020-11-16 |
| Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections XC221 100 mg, XC221 200 mg, Placebo - Acute Respiratory Viral Infections, Influenza | Phase 2 | Completed | PHARMENTERPRISES LLC | 120 | 2018-02-12 | 2019-11-04 |
Influenza, Human (3)
PHARMENTERPRISES LLC (2) · Valenta Pharm JSC (1)
Russia (3)